Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
With astonishing advances in molecular biology, cell and gene therapies represent a new class of pharmaceuticals available in the treatment of countless medical conditions. However, the success of ...
Manufacturing cell and gene therapies at hospitals in dedicated, GMP-accredited facilities would overcome many of the technical and logistical challenges associated with decentralized production. So ...
TOKYO--(BUSINESS WIRE)--PHC Corporation Biomedical Division (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura, hereinafter referred to as "Biomedical Division") will showcase a prototype ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results